IP Library Granted Patent US 9,855,236
Granted Patent B2
US 9,855,236 · App. 14/564,232 · Granted Jan 2, 2018

Pharmaceutical compositions comprising DGLA and/or 15-HETrE and methods of use thereof

Inventors: Mehar Manku (Birmingham, GB); John Climax (Dublin, IE); David Coughlan (Dublin, IE)
Assignee: DS BIOPHARMA LIMITED
A61K31/202A61K8/361A61K9/0014A61K45/06A61K47/10A61Q17/04A61Q19/004
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,855,236
App. No.
14/564,232
Granted
Jan 2, 2018
Kind
B2
Abstract

The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, and/or 15-HETrE, used singly or in combination for the prevention and/or treatment of effects associated with UV radiation such as erythema.

Claims (7)

1. A sunscreen composition comprising a UV blocker and DGLA and/or 15-HETrE, wherein the sunscreen has an increased Sun Protection Factor (SPF) compared to a sunscreen without DGLA and/or 15-HETrE.

2. The composition of claim 1 , wherein the composition comprises about 0.1 wt. % DGLA to about 20 wt. % DGLA.

3. The composition of claim 1 , wherein the composition comprises about 10 wt. % DGLA, about 1.0 wt. % DGLA, or about 0.1 wt. % DGLA.

4. The composition of claim 1 , wherein the composition comprises about 0.1 wt. % to about 50 wt. % 15-HETrE.

5. The composition of claim 1 , wherein the composition comprises about 10 wt. % 15-HETrE, about 1.0 wt. % 15-HETrE, about 0.1 wt. % 15-HETrE, or about 0.01 wt. % 15-HETrE.

6. The composition of claim 1 wherein the UV blocker is a UVA, UVB, or a UVA/UVB blocker.

7. The composition of claim 1 wherein the UV blocker is selected from the group consisting of: para aminobenzoic acid, avobenzone, cinoxate, dioxybenzone, homosalate, menthyl anthranilate, octocrylene, octyl methoxycinnamate, octyl salicylate, oxybenzone, padimate O, phenylbenzimidazole sulfonic acid, sulisobenzone, trolamine salicylate, titanium dioxide, zinc oxide, diethanolamine methoxycinnamate, digalloy trioleate, ethyl dihydroxypropyl PABA, glyceryl aminobenzoate, lawsone with dihydroxyacetone, red petrolatum, ethylhexyl triazone, dioctyl butamido triazone, benzylidene malonate polysiloxane, terephthalylidene dicamphor sulfonic acid, disodium phenyl dibenzimidazole tetrasulfonate, diethylamino hydroxybenzoyl hexyl benzoate, bis diethylamino hydroxybenzoyl benzoate, bis benzoxazoylphenyl ethylhexylimino triazine, drometrizole trisiloxane, methylene bis-benzotriazolyl tetra methylbutyl phenol, and bis-ethylhexyloxyphenol methoxyphenyltriazine, 4-methylbenzylidenecamphor, and isopentyl 4-methoxycinnamate.

Assignments (2)
CHANGE OF NAME Recorded Jul 31, 2017
From: DIGNITY SCIENCES LIMITED
To: DS BIOPHARMA LIMITED
Reel/Frame 043147/0143 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2016
From: MANKU, MEHAR; CLIMAX, JOHN; COUGHLAN, DAVID
To: DIGNITY SCIENCES LIMITED
Reel/Frame 039577/0053 →
Continuity (3)
Continuation 13655892 · Oct 19, 2012
Provisional Application 61549022 · Oct 19, 2011
Related Publication 20150093344A1 · Apr 2, 2015